Influence of IS on cumulative incidence of relapse and death and OS in first CR according to applied treatment strategy
| Outcome . | IS in JMD (%) . | IS in TKD1 (%) . | P value . |
|---|---|---|---|
| CTX/autoHSCT (no. of patients) | 75 | 28 | .056 |
| CIR after 3 years (SE) | 67 (3.0) | 86 (5.0) | .89 |
| CID after 3 years (SE) | 6.7 (1.0) | 7.1 (3.0) | .31 |
| OS after 3 years (95% CI) | 38 (28-50) | 29 (16-51) | |
| Allogeneic HSCT (no. of patients) | 48 | 27 | .10 |
| CIR after 3 years (SE) | 29 (4.0) | 49 (1.0) | .72 |
| CID after 3 years (SE) | 21 (4.0) | 23 (7.0) | .12 |
| OS after 3 years (95% CI) | 55 (43-72) | 36 (22-60) |
| Outcome . | IS in JMD (%) . | IS in TKD1 (%) . | P value . |
|---|---|---|---|
| CTX/autoHSCT (no. of patients) | 75 | 28 | .056 |
| CIR after 3 years (SE) | 67 (3.0) | 86 (5.0) | .89 |
| CID after 3 years (SE) | 6.7 (1.0) | 7.1 (3.0) | .31 |
| OS after 3 years (95% CI) | 38 (28-50) | 29 (16-51) | |
| Allogeneic HSCT (no. of patients) | 48 | 27 | .10 |
| CIR after 3 years (SE) | 29 (4.0) | 49 (1.0) | .72 |
| CID after 3 years (SE) | 21 (4.0) | 23 (7.0) | .12 |
| OS after 3 years (95% CI) | 55 (43-72) | 36 (22-60) |